Pathway to Cures, NBDF’s venture philanthropy fund, has added SeraGene to their portfolio of emerging biotech companies addressing unmet needs in the inheritable blood and bleeding disorders community. Meet the team!
SeraGene Therapeutics is a pre-clinical stage biotechnology company that develops RNA-based and nanomedicine therapies to treat blood coagulation disorders, such as bleeding disorders and thrombosis. They are working on long-lasting therapies that reduce the burden of treatment by precisely modulating the body's natural clotting proteins to restore normal blood function and improve patient quality of life.
SeraGene Therapeutics is a spin-out company from the Nanomedicines Innovation Network (NMIN) in Canada and Versiti.
The Vancouver-based company has received numerous accolades, including being named a “Company to Watch” at the 2024 Life Sciences BC Awards and winning the $3,000 Coup de Coeur prize at Sweet Pharma Day in 2024. It was a finalist in the 2025 Lily Grand Challenge.
Seragene uses proprietary RNA technology to suppress or enhance the expression of specific genes needed for coagulation. To deliver this technology, they use lipid nanoparticles (LNPs) – tiny carriers that transport the RNA directly to liver cells. This approach is designed to provide advantages over traditional treatments, including greater precision and a reduced need for frequent dosing.
For more information: SeraGene Therapeutics and Pathway to Cures.
